"Incretins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Peptides which stimulate INSULIN release from the PANCREATIC BETA CELLS following oral nutrient ingestion, or postprandially.
- Glucose-Dependent Insulin-Releasing Hormone
- Glucose Dependent Insulin Releasing Hormone
- Hormone, Glucose-Dependent Insulin-Releasing
- Insulin-Releasing Hormone, Glucose-Dependent
- Incretin Effect
- Effect, Incretin
- Incretin Effects
- Effects, Incretin
Below are MeSH descriptors whose meaning is more general than "Incretins".
Below are MeSH descriptors whose meaning is more specific than "Incretins".
This graph shows the total number of publications written about "Incretins" by people in this website by year, and whether "Incretins" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Incretins" by people in Profiles.
Identifying Behavioural Determinants to Uptake and Adherence to a Whey Protein Supplement for the Management of Type 2 Diabetes: A Qualitative Interview Study. Nutrients. 2022 Jan 27; 14(3).
Endocrine implications of bariatric surgery: a review on the intersection between incretins, bone, and sex hormones. Physiol Rep. 2019 05; 7(10):e14111.
Liraglutide-induced autoimmune hepatitis. JAMA Intern Med. 2014 Jun; 174(6):984-7.
Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus. Postgrad Med. 2014 May; 126(3):56-65.
Quantifying insulin sensitivity and entero-insular responsiveness to hyper- and hypoglycemia in ferrets. PLoS One. 2014; 9(3):e90519.
Ectopic expression of GIP in pancreatic ?-cells maintains enhanced insulin secretion in mice with complete absence of proglucagon-derived peptides. Diabetes. 2013 Feb; 62(2):510-8.
SUMO downregulates GLP-1-stimulated cAMP generation and insulin secretion. Am J Physiol Endocrinol Metab. 2012 Mar 15; 302(6):E714-23.
Cardiovascular effects of glucagonlike peptide-1 agonists. Am J Cardiol. 2011 Aug 02; 108(3 Suppl):33B-41B.
TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes. 2010 Feb; 59(2):479-85.
Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes. Am J Cardiol. 2008 Sep 01; 102(5):646-7.